Search

everythinglearnresearchcommunity

for

Search:↓

Hair loss in SLE patients is mostly due to chronic telogen effluvium and is linked to moderate disease activity.

The index to ring finger ratio may indicate disease severity in female ankylosing spondylitis patients, but not in males.

CLASI is a valid tool for assessing skin activity and damage in lupus patients.

Lower GPX4 mRNA levels are linked to higher disease activity and symptoms in lupus patients.

Machine learning can predict symptoms and quality of life in chronic skin disease patients using smartphone app data, and shows that app use varies with patient characteristics.

The document concludes that better tools are needed to measure skin disease severity in dermatomyositis and cutaneous lupus erythematosus, and introduces the DSSI and CLASI as reliable instruments.

Elental is a good long-term treatment for Crohn's disease, similar to 6-mercaptopurine but with fewer side effects.

Budesonide is not effective for maintaining remission in Crohn's disease beyond three months.

Certain proteins involved in DNA modification may affect the genetic changes in systemic lupus erythematosus and could indicate the disease's activity.

Trichoscopy is useful for diagnosing and monitoring systemic lupus erythematosus, with certain hair and scalp changes indicating more active disease.

Nrf-2-modified stem cells from hair follicles significantly improve ulcerative colitis in rats.

A patient with alopecia areata regrew hair after taking tofacitinib and showed changes in certain blood and skin markers.

Tofacitinib may help treat severe hair loss, but more research is needed.

Tofacitinib, a JAK inhibitor, improved hair regrowth in most patients with severe alopecia areata and had minimal side effects.

The ALADIN score can predict how well patients with alopecia areata will respond to JAK inhibitor treatments.

A positive anagen pull test can help detect active Lichen Planopilaris.

New treatments for hair loss are showing promise due to better understanding of genetics and the immune system.

The CLASI is a reliable tool for measuring the severity of cutaneous lupus erythematosus.

Topical tofacitinib cream may help treat certain hair loss conditions with fewer risks.

New tools and criteria have been developed to better assess and treat pediatric lupus.

Skin problems are common in lupus patients and should be treated early to prevent worsening.

Belimumab reduces disease activity, steroid use, and flares in lupus patients.

Anifrolumab treatment improves quality of life and reduces disease activity and steroid use in SLE patients.

Anti-IL-12/IL-23 antibody therapy effectively treats psoriasiform skin lesions in IBD patients.

Hair loss in lupus patients indicates higher disease activity.

Skin problems are common in Lupus patients and can indicate the disease's severity, requiring specific treatments and lifestyle changes.

Lupus is a complex disease that requires personalized treatment because it varies greatly between individuals.

The document concludes that various findings in rheumatology offer insights into disease severity, treatment responses, and potential risks in medication, with some limitations due to unspecified participant numbers.

Myositis in lupus patients is linked to skin rash, hair loss, blood issues, and high disease activity.

Oral tofacitinib can significantly improve recalcitrant lichen planopilaris.